PMLiVE5d
Researchers develop new approach to target cells affected by motor neurone disease
Researchers from the Francis Crick Institute and the UCL Queen Square Institute of Neurology have found a way to selectively ...
PMLiVE5d
NHS England begins newborn screening programme to identify rare genetic conditions
NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...
PMLiVE6d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few ...
PMLiVE6d
Beyond awareness: How employers can support those with chronic health conditions like PCOS
As part of PCOS Awareness Month, Dr Tayyibah Ali takes a look at the ways employers can help support colleagues with chronic conditions like PCOS ...
PMLiVE6d
Eli Lilly announces new $4.5bn US site for manufacturing and drug development
Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...
PMLiVE6d
How patients are transforming cancer care: insights from ESMO on patient-centric oncology
We recently had the privilege of attending the European Society for Medical Oncology (ESMO). With over 40,000 oncology professionals from 177 countries, ESMO stands as a global leader in oncology ...
PMLiVE7d
Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront
One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...
PMLiVE7d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE8d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...
PMLiVE8d
‘Causes That Count, Health’ report – key issues affecting global health
Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people around the world. So, earlier this year, purpose consultancy Revolt launched ...
PMLiVE8d
How women are revolutionising rare disease
Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges to drive progress in this often-overlooked field. Historically, women have ...
PMLiVE8d
FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients
The US Food and Drug Administration (FDA) has approved IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and paediatric ...